Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Acute Efficacy and Safety of Escitalopram Versus Desvenlafaxine and Vortioxetine in the Treatment of Depression With Cognitive Complaint: A Rater-Blinded Randomized Comparative Study

Authors
Lee, Seung-HoonJeon, Sang WonShin, CheolminPae, Chi-UnPatkar, Ashwin A.Masand, Prakash, S.An, HyongginHan, Changsu
Issue Date
Jun-2022
Publisher
대한신경정신의학회
Keywords
Depression; Cognitive complaint; Escitalopram; Desvenlafaxine; Vortioxetine; Comparative study
Citation
Psychiatry Investigation, v.19, no.4, pp.268 - 280
Indexed
SCIE
SSCI
SCOPUS
KCI
Journal Title
Psychiatry Investigation
Volume
19
Number
4
Start Page
268
End Page
280
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/55748
DOI
10.30773/pi.2021.0368
ISSN
1738-3684
Abstract
Objective This study aimed to compare the efficacy and safety of escitalopram, vortioxetine, and desvenlafaxine for acute treatment of major depressive disorder (MDD) with cognitive complaint (CC). Methods A total of 129 patients with MDD who also complained of CC were randomized evenly to either escitalopram, vortioxetine, or desvenlafaxine group and underwent a multi-center, six-week, rater-blinded, and head-to-head comparative trial. Differences in depressive symptoms following treatment were measured using the Hamilton Depression Rating Scale (HAMD) and the Montgomery-Åsberg Depression Rating Scale (MADRS). Subjective cognitive function and the presence of adverse events were assessed. Results The three antidepressant treatment groups did not show significant differences in the improvement of depressive symptoms as measured by HAMD and MADRS. Desvenlafaxine treatment was associated with a superior treatment response rate in depressive symptoms compared to vortioxetine or escitalopram treatment. However, no significant differences were found in the remission rate of depressive symptoms. The three antidepressant treatment groups did not show significant differences in the improvement of CC. Adverse profiles of each treatment group were tolerable, with no significant differences. Conclusion In acute antidepressant treatment for MDD with CC, escitalopram, vortioxetine, and desvenlafaxine presented similar efficacy in relief of depressive symptoms; however, desvenlafaxine was associated with a superior treatment. Further studies are needed to confirm these results by investigating the therapeutic efficacy and safety profile of long-term antidepressant treatment of MDD with CC (Clinical Trial Registry, http://cris.nih.go.kr/cris/en/: KCT0002173).
Files in This Item
There are no files associated with this item.
Appears in
Collections
1. Basic Science > Department of Biostatistics > 1. Journal Articles
2. Clinical Science > Department of Psychiatry > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher An, Hyong gin photo

An, Hyong gin
College of Medicine (Department of Biostatistics)
Read more

Altmetrics

Total Views & Downloads

BROWSE